Viiv weighs in on FDA approval of long-acting HIV treatment
A representative from the HIV-centered pharmaceutical company shares thoughts and perspective on the every-two-month treatment and how it might help patients.
Archives for February 22, 2022
FDA clears Immune-Onc to start trial of Keytruda combo in solid-tumor patients
The agency has given the go-ahead for a Phase I study of the company’s IO-202 antibody (in combination with Merck’s Keytruda) to treat various tumor types.